Contact

Kintra Home About Services Treatment Evidence Safety & Legal Risks Common Questions Contact Evidence, risk, and uncertainty Ayahuasca and Ibogaine: Common Questions Answered A calm, plainspoken guide to what these plant-derived psychoactive substances are, what research can and cannot show, and why safety and legal context matter. Kintra is an independent resource on ayahuasca, ibogaine, evidence, and safety. It helps adults distinguish emerging findings from established care. Start with safety, not promise. The basic distinction Two substances, different traditions and risk profiles Ayahuasca is a psychoactive brew traditionally used in Amazonian communities. It commonly combines Banisteriopsis caapi , which contains MAO-inhibiting beta-carbolines, with a DMT-containing plant such as Psychotria viridis . Oral DMT becomes active in the presence of MAO inhibition, and the experience can be intense, emotionally demanding, and commonly lasts about four to six hours. Ibogaine is an alkaloid derived from the root bark of Tabernanthe iboga , a Central African shrub with longstanding ceremonial use in Bwiti traditions. Its effects can last far longer—often 24 hours or more—and its pharmacology is complex. The history and pharmacology of ibogaine are inseparable from a major safety concern: it can prolong the QT interval and contribute to dangerous arrhythmias. Neither substance should be treated as a simple wellness product or a substitute for established care. Context matters: cultural setting, screening, medication interactions, medical history, supervision, and local law all change the risk picture. Comparison without simplification What is commonly discussed—and what should not be assumed Comparisons are useful only when they do not obscure meaningful differences. A discussion of ibogaine versus ayahuasca may help frame duration and setting, but it does not establish that either option is appropriate, effective, or safe for any individual. Ayahuasca Shorter, intens

Contact

Keep the conversation careful.